Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MKM: Modafinil, Caffeine, and Methylphenidate in Healthy Volunteers
NCT02071615Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of modafinil, methylphenidate hydrochloride extended-release chewable tablet and caffeine in attention deficit hyperactivity disorder (ADHD) and narcolepsy (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Resting state parameters of functional magnetic resonance imaging at 1 hour. Started Aug 2013; status: completed.
02
Drugs
modafinilmethylphenidate hydrochloride extended-release chewable tabletcaffeine
03
Conditions
attention deficit hyperactivity disorder (ADHD)narcolepsy
Beyond the preview
Go deeper on NCT02071615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02071615.